• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Karyopharm - oncology

Quote
anonymous said:
Good point! How does anyone leave their house and go into the field for this failure of a company? It is literary dead in the water, stock is worthless, product sucks, IC sucks, and sorry but 100 recognition points isn't motivating anyone. What's sad is they'll have you think that a $200K base salary is a lot of money, meanwhile SC and RP are making seven figures easy...all for driving the company into the ground.

Good thing is there are companies starting to buildout again...another wave of resignations on its way.
Click to expand...

RP leaves a trail of destruction everywhere he goes.
 




Honestly can we call this thing any less than a dumpster fire? How stupid does the company look firing PM? RP and SC have done absolutely NOTHING to move the company forward. Process, big pharma leadership and a company, stock, and drug that is dead in the water. Cannot wait to get my offer from SW…Amy not be ideal, but anything will beat this mess.
 




anonymous said:
Honestly can we call this thing any less than a dumpster fire? How stupid does the company look firing PM? RP and SC have done absolutely NOTHING to move the company forward. Process, big pharma leadership and a company, stock, and drug that is dead in the water. Cannot wait to get my offer from SW…Amy not be ideal, but anything will beat this mess.
Click to expand...

Regarding PM, Ricky doesn’t want anyone around who’s more capable or could possibly outshine him. Unfortunately, that eliminates at least 95% of the working age population.
 




anonymous said:
Regarding PM, Ricky doesn’t want anyone around who’s more capable or could possibly outshine him. Unfortunately, that eliminates at least 95% of the working age population.
Click to expand...


SC is no better. She is clueless and has no real experience for the position she holds. Quickly rotating through various roles at Amgen—failing at most—does not make you a competent CCO. We are seeing her lack of experience and greeness play out before us.
 
































Not quite. Compliance took the fall for those bad management decisions. Rumor has it she didn’t agree with Roche hard ass approach and peaced out to go work for King Richard, so obvious…
 




























I love how we still try to spin all this bad news. The data Dr. GS presented at ASH was mediocre at best and not fulfilling a true need in that setting.

We had to get an infusion of cash to keep afloat because this dog drug doesn’t not bring in the revenue…plain in simple.

The customers have made their mind up and we are a seldom used last ditch effort drug with not a lot of strong efficacy or activity signals. It’s a DOG. The sooner we admit that to ourselves the sooner we can recalibrate expectations…
 




anonymous said:
I love how we still try to spin all this bad news. The data Dr. GS presented at ASH was mediocre at best and not fulfilling a true need in that setting.

We had to get an infusion of cash to keep afloat because this dog drug doesn’t not bring in the revenue…plain in simple.

The customers have made their mind up and we are a seldom used last ditch effort drug with not a lot of strong efficacy or activity signals. It’s a DOG. The sooner we admit that to ourselves the sooner we can recalibrate expectations…
Click to expand...

Getting rid of the man-child Paulson would be a good first step
 




Top Bottom
Back
Quote